Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
771.120.17%
QQQ
716.510.11%
BTC/USD
64532.020.1028%
DIA
543.750.17%
GLD
392.420.71%
TLT
83.050.06%

Rigel Pharmaceuticals Inc

RIGLNASDAQ
Trade with Public
Trade with Public
$40.48
1.784.60%
At close: Aug 5, 5:00 PM EST
$40.48
N/A
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Rigel Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Rigel Pharmaceuticals (RIGL).

Price Target Range — 10 Quarters

Analyst Consensus — 6 Analysts

3Buy
3Hold
Consensus RatingBuy# Analysts6Avg. Consensus PT$44Upside to Avg. PT+9.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 2, 2026HC Wainwright & Co.Joseph PantginisMaintainedBuy$57
May 27, 2026HC Wainwright & Co.Joseph PantginisMaintainedBuy$57
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $57 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $57 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $57 price target.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $81

Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $69 to $81.
Benzinga Newsdesk

These Analysts Increase Their Forecasts On Arvinas After Q1 Results

Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Pharmaceuticals (NASDAQ:RIGL) announced global licensing agreement with Arvinas and Pfizer (NYSE:PFE) for oral PROTAC drug VEPPANU. Arvinas shares rose 1.7% on Wednesday and analysts have raised price targets.
Avi Kapoor

PRO
Citigroup Maintains Buy on Rigel Pharmaceuticals, Lowers Price Target to $69

Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and lowers the price target from $71 to $69.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved